Luteolin and triptolide: Potential therapeutic compounds for post-stroke depression via protein STAT

Zhao, Tianyang; Sun, Siqi; Gao, Yan; Yu, Rong; Wang, H; Qi, Shijie; Li, Yan

doi:10.1016/j.heliyon.2023.e18622

Cited by 1 publication

(2 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent study aimed to identify essential drug candidates targeting risk proteins based on immune-related risk GO functions and informatics algorithms (Zhao et al ., 2023). The authors, considering the risk genes of PSD, identified 335 immune-related risk GO functions and 37 compounds.…”

Section: Discussionmentioning

confidence: 99%

“…Specifically, Zhao et al . (Zhao et al ., 2023) observed that the mechanisms through which luteolin and triptolide act on STAT-related GO functions might involve three inflammatory pathways, namely hsa04010 (MAPK signaling pathway), hsa04151 (PI3K-Akt signaling pathway), and hsa04060 (Cytokine-cytokine receptor interaction). Further confirmatory experiments are deemed indispensable in the future.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A comprehensive overview of post-stroke depression treatment options

Raggi,

Serretti,

Ferri

2023

International Clinical Psychopharmacology

View full text Add to dashboard Cite

Nearly one-third of all stroke patients develop depression at any time after a stroke, and its presence is associated with unfavorable outcomes. This narrative review aims to provide a synopsis of possible pharmacological and non-pharmacological treatment modalities for post-stroke depression (PSD). Several studies have demonstrated the efficacy and safety of selective serotonin reuptake inhibitors in treating the symptoms of this clinical condition. The treatment of PSD has been recently enhanced by innovative approaches, such as cognitive-behavioral therapy, virtual reality, telehealth, repetitive transcranial magnetic stimulation, and non-conventional therapies, which might improve depression treatment in stroke survivors. Future high-quality randomized controlled trials are necessary to confirm this hypothesis.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%